The anti-EGFR nanobody D10 has an affinity of 7 nM towards human EGFR and does not compete with the binding site of Cetuximab, the approved anti-EGFR antibody for the treatment of different tumour entities such as colorectal or head and neck cancer (SCCHN). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.